Sacubitril-valsartan shows benefit in heart failure with ejection fraction of >40
- PMID: 37286705
- DOI: 10.1038/s41569-023-00897-9
Sacubitril-valsartan shows benefit in heart failure with ejection fraction of >40
Comment on
-
Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.Eur Heart J. 2023 Aug 14;44(31):2982-2993. doi: 10.1093/eurheartj/ehad344. Eur Heart J. 2023. PMID: 37210743 Free PMC article. Clinical Trial.
-
Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.J Am Coll Cardiol. 2023 Jul 4;82(1):1-12. doi: 10.1016/j.jacc.2023.04.019. Epub 2023 May 21. J Am Coll Cardiol. 2023. PMID: 37212758 Clinical Trial.
References
Original articles
-
- Mentz, R. J. et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J. Am. Coll. Cardiol. https://doi.org/10.1016/j.jacc.2023.04.019 (2023) - DOI - PubMed
-
- Vaduganathan, M. et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehad344 (2023) - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical